Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Public ClinicalTrials.gov record NCT02947347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).
Study identification
- NCT ID
- NCT02947347
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 445 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2017 (Actual)
- Primary completion
- Feb 21, 2024 (Actual)
- Completion
- Jun 9, 2025 (Actual)
- Last update posted
- Mar 17, 2026
2017 – 2025
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center | Mobile | Alabama | 36526 | — |
| City of Hope | Duarte | California | 91010 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| UCLA Hematology/Oncology | Santa Monica | California | 90095 | — |
| Helen F. Graham Cancer Center and Research Institute | Newark | Delaware | 19713 | — |
| SCRI Florida Cancer Specialists South | Fort Myers | Florida | 33916 | — |
| Florida Cancer Affiliates | Ocala | Florida | 34471 | — |
| SCRI Florida Cancer Specialists North | St. Petersburg | Florida | 33709 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Goldschmidt Cancer Center | Jefferson City | Missouri | 65109 | — |
| Southeast Nebraska Cancer Center | Lincoln | Nebraska | 68510 | — |
| OHSU Knight Cancer Institute Beaverton Clinic | Beaverton | Oregon | 97006 | — |
| Greenville Health System | Greenville | South Carolina | 29605 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404-1108 | — |
| SCRI Tennessee Oncology Nashville | Nashville | Tennessee | 37203 | — |
| Texas Oncology (Medical City) | Dallas | Texas | 75230 | — |
| Texas Oncology-Dallas Presbyterian Hospital | Dallas | Texas | 75231 | — |
| SCRI The Center For Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology (Tyler) | Tyler | Texas | 75702 | — |
| Oncology and Hematology Associates of Southwest Virginia (Blacksburg) | Blacksburg | Virginia | 24060 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Medical Oncology Associates | Spokane | Washington | 99208 | — |
| W VA University Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 103 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02947347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02947347 live on ClinicalTrials.gov.